Buy, Sell or Hold: Boston Scientific Corp (BSX-N) — Stock Predictions at Stockchase

skip to content

Home Daily Stock Opinions and Ratings Boston Scientific Corp (BSX-N)

NYSE:BSX

91.52

1.35 (1.49%) 1d

Related posts

Mixed day to end strong year Stocks rebound, yields hold 3 Best U.S. Healthcare ETFs

Investor Insights

This summary was created by AI, based on 3 opinions in the last 12 months.

Boston Scientific Corp (BSX-N) just reported a strong revenue beat with over 14.7% organic growth and raised their full-year forecast in earnings and revenues. Despite being down 1% today in the sell-off, it is still considered worth buying. Experts also emphasize the consistent gains going forward and its performance compared to other similar stocks in the market.

Consensus

Positive

Valuation

Fair Value

Similar

Medtronic Inc, MDT-N

BUY

It just reported a strong revenue beat with over 14.7% organic growth and raise their full-year forecast in earnings and revenues. Was down 1% today in the sell-off, but still worth buying.

biotechnology / pharmaceutical

BUY

BDX vs. TMO

Avoid TMO because their revenues are flattening. Both trade at a high PE. BDX hasn't done much in share movement. He'd rather pay more for Boston Scientific which performs better.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 28/22, Up 27%)

Still owns shares. Venture capital fund in health care business. One of most successful funds in biotech. Expecting consistent gains going forward.

biotechnology / pharmaceutical

HOLD

Above FMV of $40 by 22%. Growth is fairly nice. He thinks it will hold fairly well. A bouncy kind of stock.

biotechnology / pharmaceutical

DON'T BUY

It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.

biotechnology / pharmaceutical

BUY

It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.

biotechnology / pharmaceutical

TOP PICK

World's leader in med tech. He's doubling down on US healthcare. Leader in cardio surgical technology. Healthcare, neglected through Covid, will be a very high growth area for the next couple of years. No dividend. (Analysts’ price target is $49.96)

biotechnology / pharmaceutical

PARTIAL SELL

Can be a safe haven stock. Health care offers defence. But BSX has had a big run and he expects this market to roll over a bit. Take some profits and wait for opportunities, which could mean buying this back in 2-3 months. Has fantastic fundamentals, but valuation is rich.

biotechnology / pharmaceutical

BUY

Likes it very much. Higher growth. Under pressure post-earnings. Predominantly everything cardiovascular. Covid put off elective surgeries, and these are starting to return. For the rest of 2022, increased volume might offset inflationary pressures.

biotechnology / pharmaceutical

WAIT

She has owned it for many years and it has not done anything. The COVID scares cast shadows over medical procedure demand. As a medical device provider it has faced head winds. Demand should ramp back up, but it will take confidence by patients to return for procedures.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

biotechnology / pharmaceutical

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

biotechnology / pharmaceutical

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

biotechnology / pharmaceutical

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

biotechnology / pharmaceutical

Showing 1 to 15 of 58 entries

«
‹
1
2
3
4
›
»

Next Page

Boston Scientific Corp(BSX-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 3

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 3

Stockchase rating for Boston Scientific Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Boston Scientific Corp(BSX-N) Frequently Asked Questions

What is Boston Scientific Corp stock symbol?

Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N

Is Boston Scientific Corp a buy or a sell?

In the last year, 3 stock analysts published opinions about BSX-N. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Boston Scientific Corp.

Is Boston Scientific Corp a good investment or a top pick?

Boston Scientific Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Boston Scientific Corp.

Why is Boston Scientific Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Boston Scientific Corp worth watching?

3 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.

What is Boston Scientific Corp stock price?

On 2024-11-21, Boston Scientific Corp (BSX-N) stock closed at a price of $91.515.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.